The IVI-NSCLC model is coming

The Innovation and Value Initiative today announced that it is in the process of releasing a new model and value tool to evaluate treatments for for EGFR-positive non-small cell lung cancer (NSCLC).  More details on the model (named the IVI-NSCLC model) are available here, which includes a study protocol and model timeline. Oncology is an…

To get our money’s worth in healthcare, we need to collaborate

This is the title of an interesting commentary in Modern Healthcare by my colleague Mark Linthicum. An excerpt is below. In healthcare, different stakeholders have vastly different perceptions of value, with important implications for decisionmaking. An employer paying for healthcare may want to find solutions that decrease employee absences and prevent lengthy hospitalizations. A health…

How reimbursement affects innovation

Below are some excerpts from seminal papers examining how changes in reimbursement or market size affect pharmaceutical innovation. Acemoglu and Lin (2004): Our estimates suggest that a 1 percent increase in the size of the potential market for a drug category leads to a 6 percent increase in the total number of new drugs entering the…

Innovation in small markets

The introduction of new treatment technologies typically occurs where there is a large market.  A lot of innovations are developed to treat disease that affect a large number of people in the developed world because the financial returns are large.  It is less likely to observe innovation in the treatment of rare diseases or diseases…

Tackling Antimicrobial Resistance

O’Neill Commission has identified a number of recommendations to tackling drug-resistant infections. Seth Seabury and Neeraj Sood have their own thoughts on how to incentivize the development of antibiotics to fight antimicrobial resistance (AMR) which they describe in an interesting article in the Health Affairs blog. They write: The US patent system incentivizes innovation by…